Is there a meaningful serum Hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?

Hepatology

Volumn 48, Issue 5, 2008, Pages 1451-1459

  Papatheodoridis, George V ^a   Manesis, Emanuel K ^a   Manolakopoulos, Spilios ^a   Elefsiniotis, Ioannis S ^b   Goulis, John ^c   Giannousis, John ^a   Bilalis, Antonios ^d   Kafiri, Georgia ^d   Tzourmakliotis, Dimitrios ^d   Archimandritis, Athanasios J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HELENA VENIZELOU HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d KAT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT INDICATION; TREATMENT PLANNING; VIREMIA; VIRUS CARRIER; VIRUS LOAD; AGED; BIOPSY; BLOOD; DECISION SUPPORT SYSTEM; GENETICS; HEPATITIS B VIRUS; INFLAMMATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; REGRESSION ANALYSIS;

ADULT; AGED; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BIOPSY; DECISION SUPPORT TECHNIQUES; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PATIENT SELECTION; REGRESSION ANALYSIS; VIREMIA;

EID: 56149086622     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22518     Document Type: Article

References (20)

1. Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52-61.
2. Hadziyannis SJ, Papatheodoridis GV. Hepatitis Be antigen negative chronic hepatitis B - natural history and treatment. Semin Liver Dis 2006;26:130-141.
3. Pawlotsky J-M, Bastie A, Lonjon I, Remire J, Darthuy F, Soussy C-J, et al. What techniques should be used for routine detection and quantification of HBV DNA in clinical samples? J Virol Methods 1997;65:245-253.
4. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-1853.
5. Keeffe EB, Dieterich DT, Han S-HB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006;4:936-962.
6. Lok ASF, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007;45:507-539.
7. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sanguinis 2001;80:63-71.
8. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22: 696-699.
9. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: A long-term cohort study. J Hepatol 2002;36:263-270.
10. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2007;8:167-178.
11. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008;15:434-441.
12. Chu C-J, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. HEPATOLOGY 2002;36:1408-1415.
13. Lok ASF, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2001;34:1225-1241.
14. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106.
15. Lok AS, McMahon BJ. Chronic hepatitis B: Update of recommendations. HEPATOLOGY 2004;39:857-861.
16. Gish RG, Locarnini SA. Chronic hepatitis B: Current testing strategies. Clin Gastroenterol Hepatol 2006;4:666-676.
17. Manesis E, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003;98:2261-2267.
18. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47:760-767.
19. Feld JJ, Ayers M, El-Ashry D, Mazzulli T, Tellier R, Heathcote EJ. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. HEPATOLOGY 2007;46:1057-1070.
20. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of precore mutant chronic hepatitis B. J Viral Hepat 2001;8:311-321.